Haesuk Park

Haesuk Park, Ph.D.

Associate Professor

Department: Pharmaceutical Outcomes & Policy
Business Phone: (352) 273-6261
Business Email: hpark@cop.ufl.edu

About Haesuk Park

Haesuk Park, Ph.D., is an Associate Professor in the Department of Pharmaceutical Outcomes and Policy. She received her Bachelor and Master in Pharmacy from South Korea, and her Ph.D. at The University of Texas at Austin, College of Pharmacy, Health Outcomes & Pharmacy Practice. Her research centers on economic and health outcomes studies of medications and pharmaceutical care services as well as policy associated with the use of pharmaceuticals. She is passionate about investigating questions related to health policy in vulnerable populations and, particularly, how a policy affects access to care, the quality and cost of health care, and ultimately health outcomes.

Research Profile

In recent years, clinical focus of Dr. Park’s research has centered on patients with hepatitis C virus (HCV) infection, a research area with growing intensity and breadth due to the increasing awareness of the disease burden and the continuing development of new treatments. In 2018, Park received a 5-year NIH/National Institute on Drug Abuse (NIDA) K01 to build a research program in the area of HCV and health policy for individuals with substance use disorders. Currently, she also collaborated on a NIH/NHLBI R01 project to evaluate the impact of the pharmacist-led telehealthcare medication therapy management to change health outcomes in adolescents and young adults with asthma (MATCH).

Her research has received a number of awards and recognition by the professional community such as the Best New Investigator Presentation Award at the International Society for Pharmaceutical Outcomes Research (ISPOR), Best Paper Award in the Economic, Social & Administrative Sciences at the American Pharmacists Association (APhA) Annual Meeting, and the 2015 University of Florida Excellence Award for Assistant Professors. Her research interests include Pharmacoeconomics and health policy research, economic and health outcomes evaluation and meta-analysis.

Publications

2021
Calibration of Chronic Lung Disease Severity as a Risk Factor for Respiratory Syncytial Virus Hospitalization.
Journal of the Pediatric Infectious Diseases Society. 10(3):317-325 [DOI] 10.1093/jpids/piaa107. [PMID] 32978942.
2021
Changes in Schedule II oral opioid volume dispensed in a private health plan following Florida’s Acute Pain Opioid Restriction Law
Journal Of Managed Care & Specialty Pharmacy. 27(6):779-784 [DOI] 10.18553/jmcp.2021.27.6.779. [PMID] 34057389.
2021
Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study
Pharmacotherapy. [DOI] 10.1002/phar.2610. [PMID] 34170559.
2021
Health-Related Quality of Life and Health Utilities of Mild, Moderate, and Severe Asthma: Evidence from the Medical Expenditure Panel Survey
Journal of asthma and allergy. Volume 14:929-941 [DOI] 10.2147/JAA.S316278.
2021
Non-steroidal anti-inflammatory drug-associated acute kidney injury: does short-term NSAID use pose a risk in hospitalized patients?
European journal of clinical pharmacology (Internet). 77(9):1409-1417 [DOI] 10.1007/s00228-021-03121-0. [PMID] 33772627.
2021
Resource Over-Utilization in Hospitalized Patients With Uncomplicated Skin and Soft Tissue Infections
Journal of pharmacy practice. [DOI] 10.1177/08971900211000216. [PMID] 33752488.
2021
Self-reported hepatitis C(HCV) testing among people living with human immunodeficiency virus (PLWH)
Heliyon. 7(8) [DOI] 10.1016/j.heliyon.2021.e07727. [PMID] 34409188.
2021
Surveillance of patients with cirrhosis remains suboptimal in the United States
Journal of hepatology (Online). [DOI] 10.1016/j.jhep.2021.04.042. [PMID] 33965477.
2021
The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.
Hepatology (Baltimore, Md.). 74(2):566-581 [DOI] 10.1002/hep.31732. [PMID] 33544904.
2021
The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders
Journal Of Managed Care & Specialty Pharmacy. 27(7):873-881 [DOI] 10.18553/jmcp.2021.27.7.873. [PMID] 34185563.
2021
US national trends in bariatric surgery: A decade of study
Surgery. 170(1):13-17 [DOI] 10.1016/j.surg.2021.02.002. [PMID] 33714616.
2021
Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines
European Journal of Pediatrics. [DOI] 10.1007/s00431-021-04233-6. [PMID] 34365543.
2020
A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA.
Digestive diseases and sciences. 65(5):1520-1528 [DOI] 10.1007/s10620-019-05869-z. [PMID] 31598919.
2020
Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 77(3):188-195 [DOI] 10.1093/ajhp/zxz307. [PMID] 31974557.
2020
Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
Clinical therapeutics. 42(9):e161-e176 [DOI] 10.1016/j.clinthera.2020.06.022. [PMID] 32768247.
2020
Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection.
Digestive diseases and sciences. 65(11):3159-3174 [DOI] 10.1007/s10620-019-06037-z. [PMID] 31938995.
2020
Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
JAMA network open. 3(3) [DOI] 10.1001/jamanetworkopen.2020.1611. [PMID] 32211869.
2020
Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US.
Alimentary pharmacology & therapeutics. 52(10):1592-1602 [DOI] 10.1111/apt.16081. [PMID] 32931606.
2020
Medical Costs and Productivity Loss Due to Mild, Moderate, and Severe Asthma in the United States.
Journal of asthma and allergy. 13:545-555 [DOI] 10.2147/JAA.S272681. [PMID] 33149626.
2020
Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis.
European journal of clinical pharmacology. 76(6):851-866 [DOI] 10.1007/s00228-020-02854-8. [PMID] 32172363.
2020
Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States.
Diabetes, obesity & metabolism. 22(4):705-710 [DOI] 10.1111/dom.13949. [PMID] 31903713.
2020
Usability of encounter data for Medicaid comprehensive managed care vs traditional Medicaid fee-for-service claims among pregnant women.
Pharmacoepidemiology and drug safety. 29(1):30-38 [DOI] 10.1002/pds.4923. [PMID] 31737976.
2019
Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
Diabetes, obesity & metabolism. 21(1):28-36 [DOI] 10.1111/dom.13477. [PMID] 30039524.
2019
Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis.
Pharmacotherapy. 39(9):912-920 [DOI] 10.1002/phar.2311. [PMID] 31332815.
2019
Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis
Lancet Haematology. E20-E28 [DOI] 10.1016/52352-3026(18)30191-1.
2019
Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
Hepatology (Baltimore, Md.). 69(3):1032-1045 [DOI] 10.1002/hep.30303. [PMID] 30289989.
2019
Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA.
Digestive diseases and sciences. 64(3):698-707 [DOI] 10.1007/s10620-018-5326-7. [PMID] 30327963.
2019
The association between proton pump inhibitor use and the risk of tuberculosis: A case-control study.
Pharmacoepidemiology and drug safety. 28(6):830-839 [DOI] 10.1002/pds.4773. [PMID] 30920070.
2018
Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study.
Journal of affective disorders. 238:542-546 [DOI] 10.1016/j.jad.2018.06.021. [PMID] 29936394.
2018
Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis.
PloS one. 13(4) [DOI] 10.1371/journal.pone.0196452. [PMID] 29708985.
2018
Higher mortality and hospital charges in patients with cirrhosis and acute respiratory illness: a population-based study.
Scientific reports. 8(1) [DOI] 10.1038/s41598-018-28317-w. [PMID] 29967363.
2018
Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Cardiovascular diabetology. 17(1) [DOI] 10.1186/s12933-018-0746-4. [PMID] 30016946.
2018
Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015).
BMC nephrology. 19(1) [DOI] 10.1186/s12882-018-1119-7. [PMID] 30413150.
2018
Trends in Readmission Rates, Hospital Charges, and Mortality for Patients With Chronic Obstructive Pulmonary Disease (COPD) in Florida From 2009 to 2014.
Clinical therapeutics. 40(4):613-626.e1 [DOI] 10.1016/j.clinthera.2018.03.006. [PMID] 29609879.
2017
Impact of a Telephonic Outreach Program on Medication Adherence in Medicare Advantage Prescription Drug (Mapd) Plan Beneficiaries
Journal of the American Pharmacists Association. 57(1):62+-66.e2 [DOI] 10.1016/j.japh.2016.07.006.
2017
The Value of Cure Associated With Treating Treatment-Naive Chronic Hepatitis C Genotype 1: Are the New All-Oral Regimens Good Value to Society?
Liver International. 37(5):662-668 [DOI] 10.1111/liv.13298.
2016
Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care.
Medicine. 95(41) [DOI] 10.1097/MD.0000000000005048. [PMID] 27741116.
2016
Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.
Gastroenterology. 150(7):1599-1608 [DOI] 10.1053/j.gastro.2016.02.039. [PMID] 26924097.
2015
Direct Medical Costs and Utilization of Health Care Services to Treat Pneumonia in the United States: An Analysis of the 2007-2011 Medical Expenditure Panel Survey.
Clinical therapeutics. 37(7):1466-1476.e1 [DOI] 10.1016/j.clinthera.2015.04.013. [PMID] 26001310.
2015
Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
Journal of managed care & specialty pharmacy. 21(10):956-64 [PMID] 26402394.
View on: PubMed
2015
Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations
Journal Of Managed Care & Specialty Pharmacy. [DOI] 10.18553/jmcp.2015.21.6.507. [PMID] 26011552.
2015
Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations.
Journal of managed care & specialty pharmacy. 21(6):507-14 [PMID] 26011552.
View on: PubMed
2014
Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Journal of managed care & specialty pharmacy. 20(8):862-76 [PMID] 25062080.
View on: PubMed

Grants

Apr 2019 ACTIVE
A Behavioral Economic Intervention to Reduce Marijuana Use in Truant Youth
Role: Other
Funding: NATL INST OF HLTH NIDA
May 2018 ACTIVE
Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDA
May 2018 ACTIVE
Improving Medication Adherence with Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma (MATCH)
Role: Principal Investigator
Funding: NEMOURS CHILDRENS CLINIC via NATL INST OF HLTH NHLBI
Jun 2016 – Jun 2018
Work Order No. US201601
Role: Principal Investigator
Funding: PROTEUS DIGITAL HEALTH INC
Apr 2014 – Mar 2017
HCV Quality-Adjusted Cost of Care (Work Order #5)
Role: Principal Investigator
Funding: GILEAD SCIENCES

Teaching Profile

Courses Taught
2014-2021
PHA5267 Prin Pharm-Economics
2014-2021
PHA6935 Selected Topics in Pharmacy
2014-2018,2020-2021
PHA6910 Supervised Research
2014-2018,2020-2021
PHA7980 Research for Doctoral Dissertation
2014-2018,2020-2021
PHA7979 Advanced Research
2019-2021
PHA6940 Supervised Teaching
2015,2018-2021
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2014-2021
PHA6937 Topics in Pharmaceutical Administration
2014-2017,2019-2021
PHA6936 Advanced Topics in Pharmaceutical Sciences
2015-2018,2020-2021
PHA6971 Research for Master’s Thesis
2014,2018-2019
PHA6938 Research Seminar
2015,2017
PHA6266 Introduction to Pharmaceutical Outcomes and Policy II
2016
PHA5933 Select Top Pharmacy
2014-2015
PHA6279 Pharmaceutical Outcomes and Policy Seminar
2014
PHA6805 Applied Data Interpretation and Reporting of Findings in Pharmacy

Contact Details

Phones:
Business:
(352) 273-6261
Emails:
Business:
hpark@cop.ufl.edu

Recent news

UF research study examines the impact of hepatitis C virus treatment on risk of non-hepatic cancers among hepatitis C virus infected patients

Wei “Vivian” Wang, Ph.D., in the department of pharmaceutical outcomes and policy and Haesuk Park, Ph.D., an associate professor in the department, led the study.

International Day of Women in Science

The University of Florida College of Pharmacy celebrates women advancing the pharmaceutical sciences during the fifth International Day of Women and Girls in Science on Feb. 11. Five female faculty…

Congratulations to Dr. Haesuk Park on her tenure award and promotion

Park’s tenure and promotion to associate professor became official on July 1.

NIH grant will fund study of telehealth for adolescents and young adults with asthma

UF College of Pharmacy researchers will investigate whether telehealth will improve asthma medication adherence and health outcomes.